Gestational DiabetesEARLY-GLOWNCT07783178
EARLY Pregnancy GLucose prOfiles in Women With and Without GDM Risk Factors: EARLY-GLOW
An observational study of Gestational Diabetes, run by DCB Research AG at 1 site in Switzerland.
Trial summary
Background: Gestational diabetes mellitus (GDM) is associated with increased maternal and neonatal complications, including macrosomia, preeclampsia, and long-term metabolic consequences for both mother and child. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Gestational Diabetes
- How many people
- 48 participants
- Where
- 1 siteSwitzerland
- Study dates
- 19 Aug 2026to 30 Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study plans to recruit 48 pregnant women who are approximately in the 12th week of gestation (GW). Potential study participants will be stratified into two mutually exclusive groups: individuals without risk factor according to the Swiss Expertenbrief No. 8118 or at least one with the exception of age >35 years, which will not be considered for the stratification allocation. The following risks will be considered: * History of bariatric surgery * Pre-pregnancy BMI >30 kg/m² * Non-European background (Africa, Asia, Latin America) * First-degree relative with type 2 diabetes * Previous gestational diabetes * Previous macrosomic (>4000 g) offspring * Diagnosis of polycystic ovary syndrome (PCOS) or polyendocrine metabolic ovarian syndrome (PMOS) * Early pregnancy symptoms suggestive of diabetes (e.g. frequent urination, excessive thirst, glucosuria)
Who may be able to join
- Female sex
- Aged ≥18 years at inclusion
- Pregnant with singleton ≤12 GW
- Willingness to wear a CGM device for 12-16 weeks
- Signed informed consent
Who cannot join
- Pre-existing type 1 or type 2 diabetes mellitus or known prediabetes
- Diagnosis of GDM during current pregnancy
- Known allergy to adhesive materials or sensor components
- Inability to follow procedures or insufficient knowledge of project languages (German, French or English)
- Inability to give consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
DCB Research AG
Bern, Canton of Bern, 3010
Martina Rothenbühler, PhD, +41792628989, martina.rothenbuehler@dcberne.com
Stefanie Hossmann, MSc, +41794217376, stefanie.hossmann@dcberne.com
About this study
Background:
Gestational diabetes mellitus (GDM) is associated with increased maternal and neonatal complications, including macrosomia, preeclampsia, and long-term metabolic consequences for both mother and child. Current screening methods, primarily the oral glucose tolerance test (OGTT), are typically performed between 24 and 28 weeks of gestation and may miss earlier metabolic alterations. Continuous glucose monitoring (CGM) offers a detailed assessment of glucose dynamics and could potentially identify subtle dysglycemia before GDM becomes clinically apparent.
Read more
Objective:
The EARLY-GLOW study aims to characterize glucose patterns during early pregnancy and identify CGM-derived thresholds for early dysglycemia in women with and without established risk factors for GDM. The study seeks to determine whether specific combinations of glucose level and duration of hyperglycemic exposure can distinguish women at increased risk of GDM before routine diagnosis. Additionally, it will explore the relationship between glucose profiles and modifiable lifestyle factors such as diet, physical activity, sleep, and stress, while evaluating the feasibility, usability, and acceptance of CGM technology during pregnancy.
Study Design:
EARLY-GLOW is a prospective, decentralized, observational pilot study conducted in Switzerland from July 2026 to June 2027. The study will recruit 48 pregnant women with singleton pregnancies at approximately 12 weeks of gestation. Participants will be stratified into two equal groups: women with at least one recognized GDM risk factor and women without risk factors.
Methods:
Participants will wear a blinded Dexcom G7 CGM continuously from approximately gestational week 12 until routine OGTT screening between weeks 24 and 28 (up to 16 weeks of monitoring). During the study, participants will periodically record fasting blood glucose measurements, dietary intake, meal photographs, sleep quality, physical activity, stress, and well-being through REDCap questionnaires. In the final two weeks of follow-up, participants may additionally use an unblinded FreeStyle Libre 3 CGM to assess user experience. Pregnancy outcomes will be collected approximately six weeks postpartum.
Endpoints:
The primary endpoint is the identification of CGM-derived thresholds combining glucose concentration and duration of exposure that best discriminate between women with and without GDM risk factors. Secondary outcomes include the frequency and duration of hyperglycemic events, time above and below glucose target range, glycemic variability, postprandial glucose excursions, nocturnal glucose patterns, correlations with lifestyle factors, and device adherence and usability.
Read the detailed description
The EARLY-GLOW study is a prospective, decentralized observational pilot study that aims to improve understanding of glucose regulation during early pregnancy and identify early signs of gestational diabetes mellitus (GDM) before conventional diagnosis. While current GDM screening relies primarily on an oral glucose tolerance test (OGTT) performed between 24 and 28 weeks of gestation, growing evidence suggests that disturbances in glucose metabolism may already be detectable much earlier in pregnancy. Continuous glucose monitoring (CGM) offers the opportunity to capture detailed glucose patterns throughout the day and may reveal subtle abnormalities that are not identified through standard screening methods.
The study will recruit 48 pregnant women with singleton pregnancies at approximately 12 weeks of gestation from across Switzerland. Participants will be stratified into two groups: women with at least one established risk factor for GDM and women without known risk factors. Risk factors include obesity, previous gestational diabetes, a family history of type 2 diabetes, polycystic ovary syndrome, previous macrosomic offspring, bariatric surgery, and certain ethnic backgrounds associated with increased GDM risk.
After enrolment, participants will wear a blinded Dexcom G7 continuous glucose monitor for approximately 12 to 16 weeks, covering the period from early pregnancy until routine GDM screening. Because the sensor is blinded, participants will not be able to see their glucose values during the main observation period, minimizing the risk that knowledge of glucose levels influences behavior. At regular intervals, participants will also record fasting blood glucose measurements, upload meal photos, document nutritional intake, and complete questionnaires regarding sleep, stress, well-being, physical activity, and pregnancy-related symptoms. During the final two weeks of follow-up, participants may additionally wear an unblinded FreeStyle Libre 3 sensor to evaluate user experience and compare acceptance of the two most commonly used CGM systems in Switzerland.
The primary objective of the study is to identify CGM-derived thresholds that characterize early dysglycemia in pregnancy. Rather than focusing solely on a glucose value, the study aims to determine combinations of glucose level and duration of exposure that best distinguish women with and without GDM risk factors. This approach acknowledges that the clinical significance of elevated glucose levels may depend not only on how high glucose rises, but also on how long those elevations persist.
Secondary objectives include comparing the frequency and duration of hyperglycemic episodes between risk groups, assessing time spent above and below target glucose ranges, evaluating measures of glycemic variability, and characterizing postprandial and nocturnal glucose patterns. The study will also investigate the relationship between glucose profiles and lifestyle factors such as diet, sleep quality, physical activity, stress, and well-being. Furthermore, participant adherence, device wear time, comfort, usability, and acceptance of the CGM systems will be assessed to determine the feasibility of large-scale CGM use during pregnancy.
To analyze the data, researchers will use both traditional statistical methods and exploratory pattern-recognition techniques. Receiver operating characteristic (ROC) analyses will be applied to identify glucose thresholds and durations that best discriminate between women at higher and lower risk of GDM. In addition, clustering and glucose-profile analyses will be used to describe different glycemic phenotypes during pregnancy and to identify potentially clinically relevant patterns.
The study is observational, no therapeutic interventions are performed. Participants may benefit indirectly from the nutritional consultation offered at the end of the study, during which glucose data and dietary habits are reviewed with a nutrition specialist. More importantly, the knowledge generated by the study may contribute to improved screening strategies, earlier identification of women at risk for GDM, and the future development of personalized preventive interventions.
- Conditions
- Gestational Diabetes
- Keywords
- gestational diabetes, risk factors, decentralizes study, dysglycaemia
- Medical subject headings
- Diabetes, Gestational
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Pregnant women with at least one risk factor for GDM | Risk factors include obesity, previous gestational diabetes, a family history of type 2 diabetes, polycystic ovary syndrome, previous macrosomic offspring, bariatric surgery, and certain ethnic backgrounds associated with increased GDM risk. | |
| Pregnant women with no risk factors for GDM | Risk factors include obesity, previous gestational diabetes, a family history of type 2 diabetes, polycystic ovary syndrome, previous macrosomic offspring, bariatric surgery, and certain ethnic backgrounds associated with increased GDM risk. |
What is being measured
The primary outcome is the main question the study is designed to answer.
CGM-derived threshold(s) for early dysglycemia during pregnancy
Identification of one or more continuous glucose monitoring (CGM)-derived thresholds combining glucose concentration and duration of hyperglycemic exposure that best discriminate between pregnant women with and without risk factors for gestational diabetes mellitus (GDM). Thresholds will be identified using receiver operating characteristic (ROC) analyses based on CGM data collected during early pregnancy.
Measured: From 12 weeks of gestation until routine OGTT screening (24-28 weeks of gestation; up to 16 weeks of CGM monitoring)
Secondary outcomes (14)
Number of hyperglycemic events per day
Mean number of hyperglycemic events per participant per day, defined as sensor glucose values >7.8 mmol/L for at least 10 consecutive minutes.
Measured: From 12 to 28 weeks of gestation (during CGM wear period)
Time spent above 7.8 mmol/L
Average duration per day (minutes/day) with sensor glucose values >7.8 mmol/L.
Measured: From 12 to 28 weeks of gestation
Time above 7.8 mmol/L and time to >7.8 mmol/L after logged-in meals
Time after logged-in meal that individual spends >7.8 mmol/L and timing when first value postprandial >7.8 mmol/L
Measured: From 12 to 28 weeks of gestation
Time to Return to Preprandial Glucose Following Meals
Time required for postprandial glucose levels measured by continuous glucose monitoring (CGM) to return to the pre-meal glucose value after participant-logged meals.
Measured: From 12 to 28 weeks of gestation
Mean 24-hour glucose concentration
Average sensor glucose concentration (mmol/L) over a 24-hour period during the monitoring phase.
Measured: From 12 to 28 weeks of gestation
Time above range (TAR)
Percentage of time with sensor glucose values >7.8 mmol/L as measured by CGM.
Measured: From 12 to 28 weeks of gestation
Time below range (TBR)
Percentage of time with sensor glucose values <3.5 mmol/L as measured by CGM.
Measured: From 12 to 28 weeks of gestation
Glycemic variability
Glycemic variability assessed using standard deviation (SD) and coefficient of variation (CV) of CGM glucose values.
Measured: From 12 to 28 weeks of gestation
Nocturnal glucose profile
Mean nocturnal glucose concentration (mmol/L) during predefined nighttime hours.
Measured: From 12 to 28 weeks of gestation
Nocturnal hypoglycemia
Percentage of nighttime spent with sensor glucose values <3.5 mmol/L.
Measured: From 12 to 28 weeks of gestation
Association between CGM metrics and lifestyle factors
Correlation between CGM-derived glycemic metrics and participant-reported measures of dietary intake, sleep quality, physical activity, and stress.
Measured: From 12 to 28 weeks of gestation
CGM device usability and acceptance
Participant-reported usability and acceptability of Dexcom G7 and FreeStyle Libre 3, including ease of use, comfort, wearability, and overall user experience. The quesions are assessed on a scale from one to five with five being the most positive score.
Measured: End of follow-up (26-28 weeks of gestation)
CGM adherence
Adherence to CGM use measured by percentage of planned monitoring time with valid sensor data and discontinuation rates.
Measured: From 12 to 28 weeks of gestation
Device-related adverse events
Number and nature of device-related adverse events, including skin reactions and technical issues associated with CGM use.
Measured: From first sensor application until end of follow-up (up to 16 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2026
- Study start19 Aug 2026
- Primary completion30 Apr 2027 (estimated)
- Study completion30 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gestational DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- DCB Research AG
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jardena Puder, Prof, Study chair, Centre hospitalier universitaire vaudois (CHUV)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07783178
- Sponsor's protocol ID
- EARLY-GLOW
- Acronym
- EARLY-GLOW
- Status last verified
- Aug 2026
- First submitted
- 20 Aug 2026
- Last updated
- 26 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EARLY Pregnancy GLucose prOfiles in Women With and Without GDM Risk Factors: EARLY-GLOW
- ClinicalTrials.gov ID
- NCT07783178
- Acronym / sponsor ID
- EARLY-GLOW / EARLY-GLOW
- Conditions
- Gestational Diabetes
- Keywords
- gestational diabetes, risk factors, decentralizes study, dysglycaemia
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- DCB Research AGUniversity, hospital or other
- Study start
- 19 Aug 2026 (actual)
- Primary completion
- 30 Apr 2027 (estimated)
- Study completion
- 30 Apr 2027 (estimated)
- First posted
- 24 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Gestational diabetes mellitus (GDM) is associated with increased maternal and neonatal complications, including macrosomia, preeclampsia, and long-term metabolic consequences for both mother and child. Current screening methods, primarily the oral glucose tolerance test (OGTT), are typically performed between 24 and 28 weeks of gestation and may miss earlier metabolic alterations. Continuous glucose monitoring (CGM) offers a detailed assessment of glucose dynamics and could potentially identify subtle dysglycemia before GDM becomes clinically apparent.
Objective:
The EARLY-GLOW study aims to characterize glucose patterns during early pregnancy and identify CGM-derived thresholds for early dysglycemia in women with and without established risk factors for GDM. The study seeks to determine whether specific combinations of glucose level and duration of hyperglycemic exposure can distinguish women at increased risk of GDM before routine diagnosis. Additionally, it will explore the relationship between glucose profiles and modifiable lifestyle factors such as diet, physical activity, sleep, and stress, while evaluating the feasibility, usability, and acceptance of CGM technology during pregnancy.
Study Design:
EARLY-GLOW is a prospective, decentralized, observational pilot study conducted in Switzerland from July 2026 to June 2027. The study will recruit 48 pregnant women with singleton pregnancies at approximately 12 weeks of gestation. Participants will be stratified into two equal groups: women with at least one recognized GDM risk factor and women without risk factors.
Methods:
Participants will wear a blinded Dexcom G7 CGM continuously from approximately gestational week 12 until routine OGTT screening between weeks 24 and 28 (up to 16 weeks of monitoring). During the study, participants will periodically record fasting blood glucose measurements, dietary intake, meal photographs, sleep quality, physical activity, stress, and well-being through REDCap questionnaires. In the final two weeks of follow-up, participants may additionally use an unblinded FreeStyle Libre 3 CGM to assess user experience. Pregnancy outcomes will be collected approximately six weeks postpartum.
Endpoints:
The primary endpoint is the identification of CGM-derived thresholds combining glucose concentration and duration of exposure that best discriminate between women with and without GDM risk factors. Secondary outcomes include the frequency and duration of hyperglycemic events, time above and below glucose target range, glycemic variability, postprandial glucose excursions, nocturnal glucose patterns, correlations with lifestyle factors, and device adherence and usability.
Detailed description
The EARLY-GLOW study is a prospective, decentralized observational pilot study that aims to improve understanding of glucose regulation during early pregnancy and identify early signs of gestational diabetes mellitus (GDM) before conventional diagnosis. While current GDM screening relies primarily on an oral glucose tolerance test (OGTT) performed between 24 and 28 weeks of gestation, growing evidence suggests that disturbances in glucose metabolism may already be detectable much earlier in pregnancy. Continuous glucose monitoring (CGM) offers the opportunity to capture detailed glucose patterns throughout the day and may reveal subtle abnormalities that are not identified through standard screening methods.
The study will recruit 48 pregnant women with singleton pregnancies at approximately 12 weeks of gestation from across Switzerland. Participants will be stratified into two groups: women with at least one established risk factor for GDM and women without known risk factors. Risk factors include obesity, previous gestational diabetes, a family history of type 2 diabetes, polycystic ovary syndrome, previous macrosomic offspring, bariatric surgery, and certain ethnic backgrounds associated with increased GDM risk.
After enrolment, participants will wear a blinded Dexcom G7 continuous glucose monitor for approximately 12 to 16 weeks, covering the period from early pregnancy until routine GDM screening. Because the sensor is blinded, participants will not be able to see their glucose values during the main observation period, minimizing the risk that knowledge of glucose levels influences behavior. At regular intervals, participants will also record fasting blood glucose measurements, upload meal photos, document nutritional intake, and complete questionnaires regarding sleep, stress, well-being, physical activity, and pregnancy-related symptoms. During the final two weeks of follow-up, participants may additionally wear an unblinded FreeStyle Libre 3 sensor to evaluate user experience and compare acceptance of the two most commonly used CGM systems in Switzerland.
The primary objective of the study is to identify CGM-derived thresholds that characterize early dysglycemia in pregnancy. Rather than focusing solely on a glucose value, the study aims to determine combinations of glucose level and duration of exposure that best distinguish women with and without GDM risk factors. This approach acknowledges that the clinical significance of elevated glucose levels may depend not only on how high glucose rises, but also on how long those elevations persist.
Secondary objectives include comparing the frequency and duration of hyperglycemic episodes between risk groups, assessing time spent above and below target glucose ranges, evaluating measures of glycemic variability, and characterizing postprandial and nocturnal glucose patterns. The study will also investigate the relationship between glucose profiles and lifestyle factors such as diet, sleep quality, physical activity, stress, and well-being. Furthermore, participant adherence, device wear time, comfort, usability, and acceptance of the CGM systems will be assessed to determine the feasibility of large-scale CGM use during pregnancy.
To analyze the data, researchers will use both traditional statistical methods and exploratory pattern-recognition techniques. Receiver operating characteristic (ROC) analyses will be applied to identify glucose thresholds and durations that best discriminate between women at higher and lower risk of GDM. In addition, clustering and glucose-profile analyses will be used to describe different glycemic phenotypes during pregnancy and to identify potentially clinically relevant patterns.
The study is observational, no therapeutic interventions are performed. Participants may benefit indirectly from the nutritional consultation offered at the end of the study, during which glucose data and dietary habits are reviewed with a nutrition specialist. More importantly, the knowledge generated by the study may contribute to improved screening strategies, earlier identification of women at risk for GDM, and the future development of personalized preventive interventions.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pregnant women with at least one risk factor for GDM | – | –Risk factors include obesity, previous gestational diabetes, a family history of type 2 diabetes, polycystic ovary syndrome, previous macrosomic offspring, bariatric surgery, and certain ethnic backgrounds associated with increased GDM risk. |
| Pregnant women with no risk factors for GDM | – | –Risk factors include obesity, previous gestational diabetes, a family history of type 2 diabetes, polycystic ovary syndrome, previous macrosomic offspring, bariatric surgery, and certain ethnic backgrounds associated with increased GDM risk. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study plans to recruit 48 pregnant women who are approximately in the 12th week of gestation (GW). Potential study participants will be stratified into two mutually exclusive groups: individuals without risk factor according to the Swiss Expertenbrief No. 8118 or at least one with the exception of age >35 years, which will not be considered for the stratification allocation. The following risks will be considered: * History of bariatric surgery * Pre-pregnancy BMI >30 kg/m² * Non-European background (Africa, Asia, Latin America) * First-degree relative with type 2 diabetes * Previous gestational diabetes * Previous macrosomic (>4000 g) offspring * Diagnosis of polycystic ovary syndrome (PCOS) or polyendocrine metabolic ovarian syndrome (PMOS) * Early pregnancy symptoms suggestive of diabetes (e.g. frequent urination, excessive thirst, glucosuria)
Key inclusion criteria (5 listed)
- Female sex
- Aged ≥18 years at inclusion
- Pregnant with singleton ≤12 GW
- Willingness to wear a CGM device for 12-16 weeks
- Signed informed consent
Key exclusion criteria (5 listed)
- Pre-existing type 1 or type 2 diabetes mellitus or known prediabetes
- Diagnosis of GDM during current pregnancy
- Known allergy to adhesive materials or sensor components
- Inability to follow procedures or insufficient knowledge of project languages (German, French or English)
- Inability to give consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
CGM-derived threshold(s) for early dysglycemia during pregnancy
Time frame: From 12 weeks of gestation until routine OGTT screening (24-28 weeks of gestation; up to 16 weeks of CGM monitoring)
Identification of one or more continuous glucose monitoring (CGM)-derived thresholds combining glucose concentration and duration of hyperglycemic exposure that best discriminate between pregnant women with and without risk factors for gestational diabetes mellitus (GDM). Thresholds will be identified using receiver operating characteristic (ROC) analyses based on CGM data collected during early pregnancy.
14 secondary outcomes
Number of hyperglycemic events per day
Time frame: From 12 to 28 weeks of gestation (during CGM wear period)
Time spent above 7.8 mmol/L
Time frame: From 12 to 28 weeks of gestation
Time above 7.8 mmol/L and time to >7.8 mmol/L after logged-in meals
Time frame: From 12 to 28 weeks of gestation
Time to Return to Preprandial Glucose Following Meals
Time frame: From 12 to 28 weeks of gestation
Mean 24-hour glucose concentration
Time frame: From 12 to 28 weeks of gestation
Time above range (TAR)
Time frame: From 12 to 28 weeks of gestation
Time below range (TBR)
Time frame: From 12 to 28 weeks of gestation
Glycemic variability
Time frame: From 12 to 28 weeks of gestation
Nocturnal glucose profile
Time frame: From 12 to 28 weeks of gestation
Nocturnal hypoglycemia
Time frame: From 12 to 28 weeks of gestation
Association between CGM metrics and lifestyle factors
Time frame: From 12 to 28 weeks of gestation
CGM device usability and acceptance
Time frame: End of follow-up (26-28 weeks of gestation)
CGM adherence
Time frame: From 12 to 28 weeks of gestation
Device-related adverse events
Time frame: From first sensor application until end of follow-up (up to 16 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Gestational Diabetes
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Not yet recruitingObservational study
Ultrasound Assessment Of Gastric Volume In Pregnant Women Undergoing Elective Cesarean Section
Gestational Diabetes Mellitus (GDM), Obstetric Anesthesia
Active, not recruitingPhase 2
Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes
Weight Loss, Gestational Diabetes Mellitus in Pregnancy
Not yet recruiting
STRONG: SMART Trial
Gestational Diabetes Mellitus (GDM)
Not yet recruiting
A Study to Lower Blood Pressure One Year After Childbirth in Women Who Had Preeclampsia
Adverse Pregnancy Outcomes, Cardiovascular Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jardena Puder, Prof study chair
Centre hospitalier universitaire vaudois (CHUV)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gestational Diabetes, run by DCB Research AG at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Martina Rothenbühler, PhD (+41792628989, martina.rothenbuehler@dcberne.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CGM-derived threshold(s) for early dysglycemia during pregnancy (time frame: From 12 weeks of gestation until routine OGTT screening (24-28 weeks of gestation; up to 16 weeks of CGM monitoring)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.